2026-06-14T03:37:39Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/74192025-05-09T09:13:06Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608

00925njm 22002777a 4500 dc Diaz Franco, Asuncion author Diez Ruiz-Navarro, Mercedes author Bleda, Maria Jose author Aldamiz, Mikel author Camafort Babkowski, Miguel author Camino, Xabier author Cepeda, Concepcion author Costa, Asuncion author Ferrero, Oscar author Geijo, Paloma author Iribarren, José Antonio author Moreno, Santiago author Moreno, Maria Elena author Labarga, Pablo author Pinilla, Javier author Portu, Joseba author Pulido, Federico author Rosa, Carmen author Santamaría, Juan Miguel author Telenti, Mauricio author Trapiella, Luis author Trastoy, Mónica author Viciana, Pompeyo author 2010-09-14 Background: Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion. Methods: Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI). Results: A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9). Conclusions: A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed. BMC Infect Dis. 2010 Sep 14;10:267. 10.1186/1471-2334-10-267 1471-2334 BMC infectious diseases 20840743 http://hdl.handle.net/20.500.12105/7419 Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain